^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

MLL-AF4 fusion

i
Entrez ID:
Related biomarkers:
10ms
Application and prognostic relevance of CD34 detection in immunophenotyping of pediatric acute B lymphoblastic leukemia. (PubMed, Eur Rev Med Pharmacol Sci)
A higher positive rate of bone marrow CD34 expression in children with B-ALL is associated with a favorable prognosis. Children with negative CD34 expression are relatively more prone to MRD and tumor relapse after chemotherapy.
Retrospective data • Journal • IO biomarker
|
CD20 (Membrane Spanning 4-Domains A1) • CD38 (CD38 Molecule) • CD22 (CD22 Molecule) • CD33 (CD33 Molecule) • CD34 (CD34 molecule) • PBX1 (PBX Homeobox 1) • CD79A (CD79a Molecule) • MME (Membrane Metalloendopeptidase) • ANPEP (Alanyl Aminopeptidase, Membrane)
|
CD34 positive • MLL-AF4 fusion
11ms
Chromatin and aberrant enhancer activity in KMT2A rearranged acute lymphoblastic leukemia. (PubMed, Curr Opin Genet Dev)
Recent work has shown that the MLL-AF4 fusion protein drives aberrant enhancer activity at key oncogenes in ALL, dependent on the continued presence of MLL-AF4 complex components. As well as providing some general insights into enhancer function, these observations may also provide an explanation for transcriptional heterogeneity observed in MLLr patients.
Review • Journal
|
KMT2A (Lysine Methyltransferase 2A)
|
MLL rearrangement • MLL-AF4 fusion